This review highlights the value of exercise testing in nonatherosclerotic conditions such as hypertrophic cardiomyopathy, valvular heart disease, and arrhythmias.
Answers are grounded in this paper and cite their sources.
Exercise testing retains value in selected nonatherosclerotic patients without imaging; leaves open greater guideline emphasis and prospective validation.
E xercise testing first appeared in the medical literature in 1938. In clinical practice, the application of exercise testing is often combined with cardiac imaging. This is reflected in recently available appropriate use criteria for myocardial perfusion imaging and stress echocardiography. 2,3 However, exercise testing as a standalone test without imaging still has value in properly selected patients. The latest iteration of guidelines from the American College of Cardiology/American Heart Association (ACC/AHA) concerning exercise testing is dominated by diagnostic or prognostic assessments of atherosclerotic coronary artery disease applications. Less prominent are those applications that pertain to hypertrophic cardiomyopathy (HCM), valvular heart disease, and arrhythmias including pacemakers, all of which are the subject of this review.
No takes yet. Share an insight, caveat, or question.
Anthony P. Morise (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: